Liminal stops plan to advance fibrosis drug after seeing PK data

Liminal BioSciences has stopped plans to advance fezagepras in two indications after getting a look at interim pharmacokinetic results. The biotech had planned to move into a phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a phase 1b/2a study in hypertriglyceridemia next year.